RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), has announced the extension of its service offerings to include large molecule capabilities, now integrated seamlessly into its preexisting clinical pharmacology and pharmacokinetics business unit. Capabilities include pharmacodynamic studies, pharmacokinetics, biomarker assays, and immunogenicity testing, which will materially facilitate translational research efforts unique to a variety of therapeutic modalities.
To lead these new services, Tom Zhang, Ph.D., has joined Worldwide’s early phase clinical trials leadership team as Chief Scientist, Large Molecule Bioanalysis. This new role was created strategically to offer specialized, large molecule consultation for sponsors while optimizing data generation timelines and minimizing project costs.
As an industry-recognized bioanalysis expert, Dr. Zhang is responsible for actively promoting technical development programs to keep Worldwide at the forefront of technology in large molecule bioanalysis. In this role, he leads the evaluation and recommendations for analytical platforms in support of quantitative large molecule work and maintains state-of-the-art knowledge pertaining to bioanalytical methodologies.
“At Worldwide, we have a long history as a trusted market leader in early phase clinical research. Adding large molecule capabilities to our services is part of our steadfast commitment to better serve our customers,” said Mike Mencer, Executive Vice President and General Manager, Early Phase, Worldwide. “And the addition of Dr. Zhang’s deep scientific domain expertise is a vital part of this, enabling us to meet the growing demand for pharmacokinetics and immunogenicity bioanalysis due to new therapeutic classes and biosimilars. Dr. Zhang will help ensure Worldwide’s bioanalysis capabilities meet sponsors' needs within the drug development landscape to optimize the delivery of quality data and make informed decisions faster.”
With more than 12 years of industry experience, Dr. Zhang also plays a key role in supporting the expansion of Worldwide’s early phase clinical trial lab facilities. In June, Worldwide opened a new multimillion-dollar facility that reaffirms its position as a market-leading service provider for bioanalytical testing with capabilities encapsulating both large and small molecule processing.
Before joining Worldwide, Dr. Zhang served as the Head of Large Molecule Bioanalysis at WuXi AppTec and Director of Biologics and Biomarker at Frontage Laboratories. He began his career as a Senior Scientist at Roche in Shanghai after earning his Master of Science in microbial engineering from the University of Connecticut. He also holds a doctorate in biomedical engineering from Pennsylvania State University, where he is an active member of the Industrial and Professional Advisory Council. In 2021, he was honored with Penn State’s College of Engineering 40 Under 40 alumni award.
To learn more about Worldwide’s industry-recognized large molecule capabilities, click here.
About Worldwide Clinical Trials
Worldwide Clinical Trials is a global, midsize contract research organization (CRO) that provides top-performing bioanalytical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries.
Founded in 1986 by physicians committed to advancing medical science, our full-service clinical experience ranges from early phase and bioanalytical sciences through late phase studies, post-approval, and real-world evidence. Major therapeutic areas of focus include cardiovascular, metabolic, neuroscience, oncology, and rare diseases. Operating in 60+ countries with offices in North and South America, Eastern and Western Europe, and Asia, Worldwide is powered by its more than 3,000 employee experts.